logo
  

Omeros Gets CRL From FDA For Narsoplimab BLA In Treatment Of HSCT-TMA

Omeros Corp. (OMER), a commercial-stage biopharmaceutical company, Monday said it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration. The CRL is regarding its Biologics License Application or BLA for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy or HSCT-TMA.

In pre-market activity on Nasdaq, Omeros shares were losing around 13.3 percent to trade at $6.70.

Narsoplimab is the first drug candidate submitted to FDA for approval in HSCT-TMA. It has Breakthrough Therapy and Orphan designations in both HSCT-TMA and IgA nephropathy.

The company noted that patients, following hematopoietic stem cell transplantation or HSCT, generally have complex clinical courses and are often severely ill. HSCT-TMA increases that complexity and worsens outcomes. In the CRL, FDA expressed difficulty in estimating the treatment effect of narsoplimab in HSCT-TMA and asserted that additional information will be needed to support regulatory approval.

There were no chemistry, manufacturing and controls or CMC, safety, or non-clinical issues precluding approval raised in the CRL.

Omeros said it remains confident in the efficacy and safety data for narsoplimab in HSCT-TMA. The company worked closely with FDA on the clinical development plan, including with respect to both the single-arm trial to support approval and the definition of response as the primary endpoint.

The company plans to request a Type A meeting as soon as possible with FDA to discuss the CRL and determine the most expeditious path forward for the approval of narsoplimab in the treatment of HSCT-TMA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
RELATED NEWS
Follow RTT